Precision BioSciences Inc.

08/07/2026 | Press release | Distributed by Public on 08/07/2026 06:35

Initial Registration Statement for Employee Benefit Plan (Form S-8)


As filed with the Securities and Exchange Commission on August 7, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Precision BioSciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware 20-4206017
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
302 East Pettigrew Street, Suite A-100
Durham, North Carolina
27701
(Address of Principal Executive Offices) (Zip Code)
Precision BioSciences, Inc. 2019 Incentive Award Plan, as Amended and Restated
Precision BioSciences, Inc. 2019 Employee Stock Purchase Plan
(Full title of the plans)
Dario Scimeca
Chief Legal Officer & Corporate Secretary
Precision BioSciences, Inc.
302 East Pettigrew Street, Suite A-100
Durham, North Carolina 27701
(Name and address of agent for service)
(919) 314-5512
(Telephone number, including area code, of agent for service)
Copy to:
Peter N. Handrinos, Esq.
Nathan Ajiashvili, Esq.
Latham & Watkins LLP
200 Clarendon Street
Boston, Massachusetts 02116
(617) 948-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer,"


"accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


EXPLANATORY NOTE
This Registration Statement on Form S-8 (the "Registration Statement") is being filed with the Securities and Exchange Commission (the "Commission") for the purpose of registering an additional 4,900,000 shares of the Registrant's common stock, $0.000005 par value per share (the "Common Stock"), consisting of (i) 4,400,000 shares of Common Stock under the Precision BioSciences, Inc. 2019 Incentive Award Plan, as Amended and Restated (the "2019 Plan"), which includes 3,800,000 shares of Common Stock available for issuance under the 2019 Plan and an additional 600,000 shares of Common Stock that may become issuable under the 2019 Plan pursuant to its terms, and (ii) 500,000 shares of Common Stock that became or may become issuable under the Precision BioSciences, Inc. 2019 Employee Stock Purchase Plan (the "ESPP"). The additional shares registered pursuant to the 2019 Plan and the ESPP are of the same class as other securities relating to the 2019 Plan and the ESPP for which the Registration Statements on Form S-8 (File Nos. 333-230671, 333-259369, 333-267079, 333-280618, and 333-292477) filed on April 1, 2019, September 7, 2021, August 26, 2022, July 1, 2024, and December 30, 2025 respectively, are effective.
Pursuant to Instruction E of Form S-8, the contents of the above referenced prior registration statements are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein, except for Item 8, which is being updated by this Registration Statement.
Item 8. Exhibits.
Incorporated by Reference
Exhibit Number Exhibit Description Form File No. Exhibit
Filing
Date
Filed
Herewith
4.1 8-K 001-38841 3.1 04/01/2019
4.2 8-K 001-38841 3.1 02/13/2024


4.3 8-K 001-38841 3.1 05/26/2026
4.4 10-Q 001-38841 3.2 12/22/2023
4.5 S-1/A 333-230034 4.1 03/18/2019
5.1
Opinion of Latham & Watkins LLP
*
23.1
Consent of Deloitte & Touche LLP
*
23.2
Consent of Latham & Watkins LLP (included as part of Exhibit 5.1)
*
24.1
Power of Attorney (included on signature page)
*
99.1 8-K 001-38841 10.1 05/26/2026
99.2 S-1/A 333-230034 10.11 03/18/2019
107.1
Filing Fee Table
*
* Filed herewith.


SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on this 7th day of August, 2026.
PRECISION BIOSCIENCES, INC.
By: /s/ Dario Scimeca
Dario Scimeca
Chief Legal Officer & Corporate Secretary
KNOW ALL MEN BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Michael Amoroso, John Alexander Kelly, and Dario Scimeca, and each of them, his true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this


Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Name Title Date
/s/ Michael Amoroso
Michael Amoroso
President and Chief Executive Officer and Director
(principal executive officer)
August 7, 2026
/s/ Naresh Tanna
Naresh Tanna
Chief Financial Officer
(principal financial officer)
August 7, 2026
/s/ Mei Burris
Mei Burris
Vice President of Finance and Chief Accounting Officer
(principal accounting officer)
August 7, 2026
/s/ Melinda Brown Director August 7, 2026
Melinda Brown
/s/ Kevin J. Buehler
Kevin J. Buehler
Director August 7, 2026
/s/ Stanley R. Frankel
Stanley R. Frankel, M.D.
Director August 7, 2026
/s/ Geno Germano
Geno Germano
Director August 7, 2026
/s/ Shari Lisa Piré
Shari Lisa Piré
Director August 7, 2026

Precision BioSciences Inc. published this content on August 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 07, 2026 at 12:35 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]